EUVIMEDEUVIMED entdecken
Vergleichsstudie

Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients

Xiaoyi Guo, Xu Liang, Ben Li, Yan Mao, Nina Zhou, Jiayue Liu, Guangjie Yang, Zhenguang Wang, Guohong Song, Zhi Yang iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07251-w ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Xiaoyi Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Capital's Funds for Health Improvement and Research, the Pilot Project (4 th Round) to Reform Public Development of Beijing Municipal Medical Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To assess the diagnostic performance and the whole-body heterogeneity of HER2 expression on Al18F-NOTA-HER2-BCH PET/CT in patients with HER2-low breast cancer. METHODS: In this prospective study conducted from November 2021 to March 2024, participants with HER2-low breast cancer underwent both Al18F-NOTA-HER2-BCH and 18F-FDG PET/CT. Participants were pathologically confirmed as HER2-low (immunohistochemistry score of 1 + or 2 + without HER2 gene amplification on in situ hybridization). PET/CT images were acquired 3.5 h after injection of 200 MBq of Al18F-NOTA-HER2-BCH. The maximum standardized uptake value (SUVmax) and target-to-background ratios (TBR) were used to quantify tracer uptake. RESULTS: Fifty-two participants with HER2-low breast cancer (mean age, 53.0 ± 11.0; 52 females) underwent Al18F-NOTA-HER2-BCH and 18F-FDG PET/CT with paired tumor biopsies. No adverse events occurred. The median SUVmax and TBR of 52 HER2-low biopsy lesions on Al18F-NOTA-HER2-BCH PET/CT were lower than that on 18F-FDG PET/CT (6.6 vs. 10.5, P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18Heterocyclic Compounds, 1-RingHeterocyclic CompoundsHumansMiddle AgedFemaleAdultAgedProspective StudiesFluorine Radioisotopes

Stichwörter der Autor:innen

18F-FDGAl18F-NOTA-HER2-BCHBreast cancerHER2-lowPET/CT

Substanzen

Erb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18Heterocyclic Compounds, 1-RingHeterocyclic CompoundsFluorine RadioisotopesERBB2 protein, human1,4,7-triazacyclononane-N,N',N''-triacetic acid

Autor:innen und Institutionen

  • Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluat…
  • Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, No.59, Haier Road, Qingdao, Shandong, 266061, China.
  • Breast Disease Center, The Affiliated Hospital of Qingdao University, No.59, Haier Road, Qingdao, Shandong, 266061, China.
  • Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, No.59, Haier Road, Qingdao, Shandong, 266061, China. wangzhenguang@qdu.edu.cn.
  • Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. songguohong918@hotmail.com.

ORCID-Profile: Zhi Yang

Förderung

  • National Natural Science Foundation of China
  • the Capital's Funds for Health Improvement and Research
  • the Pilot Project (4 th Round) to Reform Public Development of Beijing Municipal Medical Research Institute
  • and Science Foundation of Peking University Cancer Hospital
  • Isotope and Pharmaceutical Innovation Fund of National Engineering Research Center of Isotope & Pharmaceutical
  • Nuclear energy development research project
  • the Capital’s Funds for Health Improvement and Research

Zitieren

APA

Guo, X., Liang, X., Li, B., Mao, Y., Zhou, N., Liu, J., Yang, G., Wang, Z., Song, G., & Yang, Z. (2025). Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07251-w

Vancouver

Guo X, Liang X, Li B, Mao Y, Zhou N, Liu J, et al. Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07251-w

BibTeX
@article{Guo2025,
  author = {Guo, Xiaoyi and Liang, Xu and Li, Ben and Mao, Yan and Zhou, Nina and Liu, Jiayue and Yang, Guangjie and Wang, Zhenguang and Song, Guohong and Yang, Zhi},
  title = {Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07251-w}
}
Kostenlos starten →